{
    "nctId": "NCT03442504",
    "briefTitle": "Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer",
    "officialTitle": "Evaluation Study of the Prediction of the Response to Second-line Hormone Therapy by 16\u03b1- [18F] Fluoro-17\u03b2-estradiol (FES) PET in Patients With Metastatic Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 57,
    "primaryOutcomeMeasure": "Determine the predictive value of PET at the \"lesion\" level",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Primary breast tumor (ductal or lobular) expressing immunohistochemistry of hormone receptors (RP + and / or RE +, with significance level \u2265 10%) but not overexpressing HER2,\n2. Metastatic stage with at least one lesion identifiable on the conventional balance sheet other than a liver injury,\n3. Patient progressing under a 1st line of hormone therapy,\n4. Patient candidate for a new second-line hormonal treatment,\n5. Postmenopausal patient,\n6. Karnofsky \u2265 70 or ECOG 0-1\n7. Life expectancy of at least 6 months\n8. Creatinine \\<= 2.5 normal\n9. Social insured patient\n10. Signed informed consent\n\nExclusion Criteria:\n\n1. HER2 overexpressing primary tumor in immunohistochemistry,\n2. Tumor that does not significantly (\\<10%) express the hormonal receptors,\n3. Hormonal treatment in progress,\n4. Contraindication to a new second-line hormonal treatment,\n5. Patient receiving or likely to receive second-line chemotherapy in the course of the evolution of her breast cancer,\n6. Persons deprived of liberty or guardianship,\n7. Impossibility of submitting to the medical examination of the test for geographical, social or psychological reasons,\n8. Serious illness or comorbidity assessed at risk,\n9. History of cancer within 5 years, with the exception of cutaneous carcinomas other than melanomas, or carcinoma in situ of the cervix,\n10. Intellectual inability to sign informed consent.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}